| 000 | 00949 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250516071609.0 | ||
| 264 | 0 | _c20120117 | |
| 008 | 201201s 0 0 eng d | ||
| 022 | _a1128-3602 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTirelli, U | |
| 245 | 0 | 0 |
_aGrouping of molecularly targeted anti-cancer agents based on cost-effectiveness analysis. _h[electronic resource] |
| 260 |
_bEuropean review for medical and pharmacological sciences _cNov 2011 |
||
| 300 |
_a1355-6 p. _bdigital |
||
| 500 | _aPublication Type: Letter | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xeconomics |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMolecular Targeted Therapy _xeconomics |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 | _aSurvival |
| 700 | 1 | _aBerretta, M | |
| 700 | 1 | _aBearz, A | |
| 700 | 1 | _aCarbone, A | |
| 773 | 0 |
_tEuropean review for medical and pharmacological sciences _gvol. 15 _gno. 11 _gp. 1355-6 |
|
| 999 |
_c21415895 _d21415895 |
||